{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:18:44Z","timestamp":1791778724623,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T00:00:00Z","timestamp":1304380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s11864-011-0156-2","type":"journal-article","created":{"date-parts":[[2011,5,2]],"date-time":"2011-05-02T05:34:30Z","timestamp":1304314470000},"page":"230-239","source":"Crossref","is-referenced-by-count":4,"title":["Management of Meningeal Neoplasms: Meningiomas and Hemangiopericytomas"],"prefix":"10.1007","volume":"12","author":[{"given":"Zanetta","family":"Lamar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,3]]},"reference":[{"key":"156_CR1","first-page":"164","volume-title":"WHO classification of tumours of the central nervous system","author":"A Perry","year":"2007","unstructured":"Perry A, Louis DN, Scheithauer BW, Budka H, von Meningiomas DA. In: Louis D, Ohgaki H, Wiestler O, Webster C, editors. WHO classification of tumours of the central nervous system. 4th ed. France: International Agency for Research on Cancer; 2007. p. 164\u201380.","edition":"4"},{"key":"156_CR2","unstructured":"Park J, Black P. Primary meningeal neoplasms. Principles of neuro-oncology. In: Schiff D, Oneil P, editors. United States: McGraw-Hill; 2005. p. 371\u201377."},{"key":"156_CR3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-010-0342-2","volume":"99","author":"C Mawrin","year":"2010","unstructured":"Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neuro Oncol. 2010;99:379\u201391.","journal-title":"J Neuro Oncol"},{"issue":"3","key":"156_CR4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11060-009-9934-0","volume":"95","author":"A Durand","year":"2009","unstructured":"Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamarid\u00e8s M, Menei P, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009;95(3):367\u201375.","journal-title":"J Neurooncol"},{"issue":"3","key":"156_CR5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11060-010-0367-6","volume":"99","author":"D Saloner","year":"2010","unstructured":"Saloner D, Uzelac A, Hetts S, Martin A, Dillon W. Modern meningioma imaging techniques. J Neurooncol. 2010;99(3):333\u201340.","journal-title":"J Neurooncol"},{"key":"156_CR6","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s00259-009-1133-x","volume":"36","author":"J Lee","year":"2009","unstructured":"Lee J, Kang K, Park S, Lee S, Paeng J, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1574\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"156_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11060-006-9210-5","volume":"81","author":"N Nathoo","year":"2007","unstructured":"Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH, et al. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2007;81(2):167\u201374.","journal-title":"J Neurooncol."},{"issue":"5","key":"156_CR8","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3171\/2010.3.JNS091966","volume":"113","author":"ME Sughrue","year":"2010","unstructured":"Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113(5):1036\u201342. This study highlights the importance of observation during the course of treatment for small asymptomatic meningiomas, particularly those with an initial diameter < 2 cm.","journal-title":"J Neurosurg"},{"key":"156_CR9","doi-asserted-by":"crossref","unstructured":"Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22\u201339.","DOI":"10.1136\/jnnp.20.1.22"},{"issue":"5","key":"156_CR10","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3171\/2010.2.JNS10280","volume":"113","author":"ME Sughrue","year":"2010","unstructured":"Sughrue ME, Kane AJ, Shangari G, Rutkowski MJ, McDermott MW, Berger MS, et al. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg. 2010;113(5):1026\u20137. This study investigated the relevance of aggressive surgical techniques in the treatment of Grade I meningiomas and found that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with more conservative surgical measures.","journal-title":"J Neurosurg"},{"key":"156_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3171\/2010.1.JNS091114","volume":"113","author":"ME Sughrue","year":"2010","unstructured":"Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg. 2010;113:202\u20139.","journal-title":"J Neurosurg"},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/cncr.11645","volume":"98","author":"WM Mendenhall","year":"2003","unstructured":"Mendenhall WM, Morris CG, Amdur RJ, Foote KD, Friedman WA. Radiotherapy alone or after subtotal resection for benign skull base meningiomas. Cancer. 2003;98:1473\u201382.","journal-title":"Cancer"},{"issue":"4","key":"156_CR13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1748-717X-4-42","volume":"14","author":"G Minnitti","year":"2009","unstructured":"Minnitti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiot Oncol. 2009;14(4):42.","journal-title":"Radiot Oncol"},{"key":"156_CR14","doi-asserted-by":"crossref","unstructured":"Pannullo SC, Fraser JF, Moliterno J, Cobb W, Stieg PE. Stereotactic radiosurgery: A meta-analysis of current therapeutic applications in neuro-oncologic disease. J Neurooncol. 2010; Epub ahead of print","DOI":"10.1007\/s11060-010-0360-0"},{"key":"156_CR15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1440-1789.2009.01047.x","volume":"30","author":"CGS Le\u00e3es","year":"2010","unstructured":"Le\u00e3es CGS, Meurer RT, Coutinho LB, Ferreira N, et al. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. Neuropathology. 2010;30:44\u20139.","journal-title":"Neuropathology"},{"issue":"1","key":"156_CR16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","volume":"15","author":"J Goodwin","year":"1993","unstructured":"Goodwin J, Crowley J, Eyre H, Stafford B, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75\u20137.","journal-title":"J Neurooncol"},{"issue":"8","key":"156_CR17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"S Grunberg","year":"2006","unstructured":"Grunberg S, Weiss M, Russell C, Spitz I, Ahmadi J, Sadun A, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Investigation. 2006;24(8):727\u201333.","journal-title":"Cancer Investigation"},{"issue":"10","key":"156_CR18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","volume":"69","author":"MC Chamberlain","year":"2007","unstructured":"Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969\u201373.","journal-title":"Neurology."},{"issue":"5","key":"156_CR19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3171\/jns.1997.86.5.0845","volume":"86","author":"UM Schrell","year":"1997","unstructured":"Schrell UM, Rittig MG, Anders M, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997;86(5):845\u201352.","journal-title":"J Neurosurg"},{"issue":"5","key":"156_CR20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3171\/jns.1997.86.5.0840","volume":"86","author":"UM Schrell","year":"1997","unstructured":"Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86(5):840\u20134.","journal-title":"J Neurosurg."},{"issue":"4","key":"156_CR21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0028-3770(04)98326-9","volume":"50","author":"S Fuentes","year":"2004","unstructured":"Fuentes S, Chinot O, Dufour H, Paz-Paredes A, M\u00e9tellus P, Barrie-Attarian M, et al. Hydroxyurea treatment for unresectable meningioma. Neurochirurgie. 2004;50(4):461\u20137.","journal-title":"Neurochirurgie."},{"key":"156_CR22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","volume":"67","author":"D Loven","year":"2004","unstructured":"Loven D, Hardoff R, Sever ZB, Steinmetz AP, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67:221\u20136.","journal-title":"J Neurooncol"},{"key":"156_CR23","doi-asserted-by":"crossref","unstructured":"Mason WP, Gentill F, Macdonald DR, Hariharan S, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 2002;97:341\u2013346, 200","DOI":"10.3171\/jns.2002.97.2.0341"},{"issue":"4","key":"156_CR24","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","volume":"23","author":"HB Newton","year":"2007","unstructured":"Newton HB. Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus. 2007;23(4):E11.","journal-title":"Neurosurg Focus"},{"issue":"5","key":"156_CR25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/02688690400012392","volume":"18","author":"HB Newton","year":"2004","unstructured":"Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18(5):495\u20139.","journal-title":"Br J Neurosurg."},{"issue":"2","key":"156_CR26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1054\/jocn.2001.1019","volume":"9","author":"MA Rosenthal","year":"2002","unstructured":"Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9(2):156\u20138.","journal-title":"J Clin Neurosci."},{"issue":"3","key":"156_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-2006-949518","volume":"16","author":"GJ Weston","year":"2006","unstructured":"Weston GJ, Martin AJ, Mufti GJ, Strong AJ, Gleeson MJ. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 2006;16(3):157\u201360.","journal-title":"Skull Base."},{"issue":"3","key":"156_CR28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3171\/jns.2007.106.3.455","volume":"106","author":"V Gupta","year":"2007","unstructured":"Gupta V, Su YS, Samuelson CG, Liebes LF, Chamberlain MC. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007;106(3):455\u201362.","journal-title":"J Neurosurg."},{"issue":"3","key":"156_CR29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","volume":"78","author":"MC Chamberlain","year":"2006","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3):271\u20136.","journal-title":"J Neurooncol."},{"key":"156_CR30","doi-asserted-by":"crossref","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;13;62(7):1210\u20132.","DOI":"10.1212\/01.WNL.0000118300.82017.F4"},{"issue":"8","key":"156_CR31","first-page":"2269","volume":"7","author":"C Muhr","year":"2001","unstructured":"Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, L\u00e5ngstr\u00f6m B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7(8):2269\u201376.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"156_CR32","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","volume":"113","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC, Glantz MJ. Interferon-\u03b1 for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113(8):2146\u201351.","journal-title":"Cancer."},{"issue":"6","key":"156_CR33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","volume":"11","author":"PY Wen","year":"2009","unstructured":"Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01\u201308). J Neuro Oncol. 2009;11(6):853\u201360.","journal-title":"J. Neuro Oncol."},{"key":"156_CR34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","volume":"96","author":"A Norden","year":"2010","unstructured":"Norden A, Raizer J, Abrey L, Lamborn K, Wen P, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96:211\u20137.","journal-title":"J Neurooncol"},{"issue":"2","key":"156_CR35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/2010.3.JNS091882","volume":"113","author":"MJ Rutkowski","year":"2010","unstructured":"Rutkowski MJ, Sughrue ME, Kane AJ, Aranda D, et al. Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg. 2010;113(2):333\u20139. This study highlights the importance of gross total resection, and its superior survival advantage as compared to subtotal resection and post-operative radiation in patients with hemangiopericytomas.","journal-title":"J Neurosurg."},{"key":"156_CR36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11060-010-0114-z","volume":"99","author":"J Kim","year":"2010","unstructured":"Kim J, Kim D, Chung H-T, et al. Gamma Knife stereotactic radiosurgery for intracranial hemangiopericytomas. J Neurooncol. 2010;99:115\u201322.","journal-title":"J Neurooncol"},{"key":"156_CR37","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/cncr.20109","volume":"100","author":"S Soyuer","year":"2004","unstructured":"Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH. Intracranial meningeal hemangiopericytoma: the role of radiotherapy. Cancer. 2004;100:1491\u20137.","journal-title":"Cancer"},{"issue":"4","key":"156_CR38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1227\/01.NEU.0000325494.69836.51","volume":"63","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. NEU. 2008;63(4):720\u20136.","journal-title":"NEU."},{"key":"156_CR39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000307468","volume":"3","author":"KB Peters","year":"2010","unstructured":"Peters KB, McLendon R, Morse MA, Vredenburgh JJ. Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: a case report. Case Rep Oncol. 2010;3:93\u20137.","journal-title":"Case Rep Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-011-0156-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0156-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T15:01:03Z","timestamp":1686063663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-011-0156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s11864-011-0156-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,3]]}}}